Korean J Gastroenterol.  2014 Aug;64(2):93-97. 10.4166/kjg.2014.64.2.93.

Differences in the Prognosis according to the Periods of Diagnosis in Ulcerative Colitis

• Chae HB
• Jung YS
• Park DI
• Lee CK
• Huh KC
• Shin JE
• Kim JH
• Kim YS
• Jung Y
• Jung SA
• Song HJ
• Jang HJ
• Hong SN
• Kim YH

• KMID: 2164419
• DOI: http://doi.org/10.4166/kjg.2014.64.2.93

Abstract

BACKGROUND/AIMS
Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC. The aim of this study was to investigate the differences of medication use and prognosis in UC patients according to the periods of diagnosis.
METHODS
From 1987 to 2012, a total of 1,422 patients with UC were retrospectively reviewed in 12 hospitals. The study population was divided into two groups according to the periods of diagnosis as follows; group A: 1987-2005, group B: 2006-2012. Analyzed variables were compared by using chi-square test and logistic regression analysis.
RESULTS
Mean age of the subjects was 42.2 years, and the mean follow-up period was 4.7 years. In univariate analysis, the use of infliximab in group B was significantly higher than group A (4.5% vs. 7.6%, p=0.016), and UC-related hospitalization (45.8% vs. 40.1%, p=0.031) and UC-related surgery (6.4% vs. 3.5%, p=0.010) in group B was significantly lower than that of group A. The use of oral steroid in surgery group was significantly higher than non-surgery group in multivariate analysis (OR 1.85, 95% CI 1.03-3.30, p=0.039).
CONCLUSIONS
Infliximab might play an important role for the treatment of steroid-refractory UC. Well-designed prospective trials based on the efficacy and safety of infliximab are required in the future.

Keyword

Ulcerative colitis; Infliximab; Steroid, refractory; Surgery

MeSH Terms

Adult
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Colitis, Ulcerative/*diagnosis/drug therapy/pathology
Female
Follow-Up Studies
Hospitalization
Humans
Infliximab/therapeutic use
Logistic Models
Male
Mesalamine/therapeutic use
Middle Aged
Odds Ratio
Prognosis
Retrospective Studies
Time Factors
Anti-Inflammatory Agents, Non-Steroidal
Infliximab
Mesalamine

Reference

References

1. Chaparro M, Burgueño P, Iglesias E, et al. Infliximab salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther. 2012; 35:275–283.

2. Yamamoto S, Nakase H, Matsuura M, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. J Gastroenterol Hepatol. 2010; 25:886–891.

3. Yamamoto-Furusho JK, Uzcanga LF. Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids. Dig Surg. 2008; 25:383–386.

4. Choi CH, Kim YH, Kim YS, et al. IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Guidelines for the management of ulcerative colitis. Korean J Gastroenterol. 2012; 59:118–140.

5. Leijonmarck CE, Persson PG, Hellers G. Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut. 1990; 31:329–333.

6. Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013; 19:1858–1866.

7. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. 2008; 40:821–826.

8. Lv R, Qiao W, Wu Z, et al. Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a metaanalysis. PLoS One. 2014; 9:e86692.

9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353:2462–2476.

10. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009; 137:1250–1260. quiz 1520.

11. Choi CH, Jung SA, Lee BI, Lee KM, Kim JS, Han DS. IBD Study Group of the Korean Association of the Study of Intestinal Diseases. Diagnostic guideline of ulcerative colitis. Korean J Gastroenterol. 2009; 53:145–160.

12. Ho GT, Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006; 24:319–330.

13. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955; 2:1041–1048.

14. Cho JH, Lee CK, Kim HJ, et al. Efficacy of infliximab rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: single center experience. Intest Res. 2012; 10:152–160.

15. Monterubbianesi R, Aratari A, Armuzzi A, et al. On behalf of the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Infliximab three-dose induction regimen in severe corti-costeroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy. J Crohns Colitis. 2014; 8:852–858.

16. Lakatos PL, Golovics PA, David G, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977–2009. Am J Gastroenterol. 2012; 107:579–588.

17. Chhaya V, Pollok R. The impact of thiopurines on surgical outcomes in inflammatory bowel disease: do they make a difference? F1000Prime Rep. 2013; 5:50.